-
1
-
-
84873084648
-
-
CDC. 2012 pink book
-
CDC. 2012 pink book, pneumococcal disease. www.cdc.gov/vaccines/pubs/ pinkbook/downloads/pneumo.pdf.
-
Pneumococcal Disease
-
-
-
2
-
-
0031552194
-
Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
-
CDC
-
CDC. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46(RR-8):1-24.
-
(1997)
MMWR Recomm Rep
, vol.46
, Issue.RR-8
, pp. 1-24
-
-
-
4
-
-
77956405554
-
Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23)
-
CDC. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010;59(34):1102-6.
-
(2010)
MMWR Morb Mortal Wkly Rep
, vol.59
, Issue.34
, pp. 1102-1106
-
-
-
5
-
-
1242282920
-
Pneumococcal polysaccharide vaccine
-
Plotkin SA, Orenstein WA, eds. Vaccines. 4th ed
-
Fedson D, Musher D. Pneumococcal polysaccharide vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. 4th ed. Philadelphia: Saunders, 2004.
-
(2004)
Philadelphia Saunders
-
-
Fedson, D.1
Musher, D.2
-
6
-
-
58849088139
-
Eff?cacy of pneumococcal vaccination in adults: A meta-analysis
-
Huss A, Scott P, Stuck AE, Trotter C, Egger M. Eff?cacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009;180(1):48-58.
-
(2009)
CMAJ
, vol.180
, Issue.1
, pp. 48-58
-
-
Huss, A.1
Scott, P.2
Stuck, A.E.3
Trotter, C.4
Egger, M.5
-
8
-
-
55049089930
-
Rationale and design of CAPITA: A RCT of 13-valent conjugated pneumococcal vaccine eff?cacy among older adults
-
Hak E, Grobbee DE, Sanders EA, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine eff?cacy among older adults. Neth J Med 2008;66(9):378-83.
-
(2008)
Neth J Med
, vol.66
, Issue.9
, pp. 378-383
-
-
Hak, E.1
Grobbee, D.E.2
Sanders, E.A.3
-
9
-
-
82555164974
-
Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. CDC
-
Ahmed F, Temte JL, Campos-Outcalt D, Schunemann HJ. Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. CDC. Vaccine 2011;29(49):9171-6.
-
(2011)
Vaccine
, vol.29
, Issue.49
, pp. 9171-9176
-
-
Ahmed, F.1
Temte, J.L.2
Campos-Outcalt, D.3
Schunemann, H.J.4
-
10
-
-
0036377943
-
Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than f?ve years of age for prevention of pneumonia
-
Black SB, Shinef?eld HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than f?ve years of age for prevention of pneumonia. Pediatr Infect Dis J 2002;21(9): 810-5.
-
(2002)
Pediatr Infect Dis J
, vol.21
, Issue.9
, pp. 810-815
-
-
Black, S.B.1
Shinefeld, H.R.2
Ling, S.3
-
11
-
-
79951812325
-
Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: No evidence of hyporesponsiveness
-
Hammitt LL, Bulkow LR, Singleton RJ, et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine 2011;29(12):2287-95.
-
(2011)
Vaccine
, vol.29
, Issue.12
, pp. 2287-2295
-
-
Hammitt, L.L.1
Bulkow, L.R.2
Singleton, R.J.3
-
12
-
-
27244440305
-
Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine
-
Lexau CA, Lynf?eld R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005;294(16):2043-51.
-
(2005)
JAMA
, vol.294
, Issue.16
, pp. 2043-2051
-
-
Lexau, C.A.1
Lynfeld, R.2
Danila, R.3
-
13
-
-
71949103062
-
Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine
-
Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201(1):32-41.
-
(2010)
J Infect Dis
, vol.201
, Issue.1
, pp. 32-41
-
-
Pilishvili, T.1
Lexau, C.2
Farley, M.M.3
-
14
-
-
84856982358
-
Adult vaccination coverage-U.S.,2010
-
CDC. Adult vaccination coverage-U.S.,2010. MMWR Morb Mortal Wkly Rep 2012;61(4):66-72.
-
(2012)
MMWR Morb Mortal Wkly Rep
, vol.61
, Issue.4
, pp. 66-72
-
-
-
15
-
-
84863393658
-
Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine
-
Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012;307(8):804-12.
-
(2012)
JAMA
, vol.307
, Issue.8
, pp. 804-812
-
-
Smith, K.J.1
Wateska, A.R.2
Nowalk, M.P.3
Raymund, M.4
Nuorti, J.P.5
Zimmerman, R.K.6
-
16
-
-
39749203434
-
Alternative strategies for adult pneumococcal polysaccharide vaccination: A cost-effectiveness analysis
-
Smith KJ, Zimmerman RK, Lin CJ, et al. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine 2008;26(11):1420-31.
-
(2008)
Vaccine
, vol.26
, Issue.11
, pp. 1420-1431
-
-
Smith, K.J.1
Zimmerman, R.K.2
Lin, C.J.3
-
17
-
-
84893064025
-
-
Hyattsville MD National Center for Health Statistics
-
Arias E. U.S. life tables, 2006. National vital statistics reports; vol. 58, no. 21. Hyattsville MD: National Center for Health Statistics, 2010.
-
(2006)
National Vital Statistics Reports
, vol.58
, Issue.21
-
-
Arias, E.U.S.1
Tables, L.2
-
19
-
-
0037073586
-
Comparing potential benef?ts of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly
-
Fry AM, Zell ER, Schuchat A, Butler JC, Whitney CG. Comparing potential benef?ts of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine 2002;21(3-4):303-11.
-
(2002)
Vaccine
, vol.21
, Issue.3-4
, pp. 303-311
-
-
Fry, A.M.1
Zell, E.R.2
Schuchat, A.3
Butler, J.C.4
Whitney, C.G.5
-
21
-
-
34047096257
-
Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the U.S. A timeseries analysis
-
Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griff?n MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the U.S.: a timeseries analysis. Lancet 2007;369(9568):1179-86.
-
(2007)
Lancet
, vol.369
, Issue.9568
, pp. 1179-1186
-
-
Grijalva, C.G.1
Nuorti, J.P.2
Arbogast, P.G.3
Martin, S.W.4
Edwards, K.M.5
Griffn, M.R.6
-
22
-
-
78249253037
-
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the U.S
-
Rubin JL, McGarry LJ, Strutton DR, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the U.S. Vaccine 2010;28(48):7634-43.
-
(2010)
Vaccine
, vol.28
, Issue.48
, pp. 7634-7643
-
-
Rubin, J.L.1
McGarry, L.J.2
Strutton, D.R.3
-
23
-
-
77954757935
-
Clinical and economic burden of pneumococcal disease in older U.S. Adults
-
Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older U.S. adults. Vaccine 2010;28(31):4955-60.
-
(2010)
Vaccine
, vol.28
, Issue.31
, pp. 4955-4960
-
-
Weycker, D.1
Strutton, D.2
Edelsberg, J.3
Sato, R.4
Jackson, L.A.5
-
24
-
-
84860372845
-
Aging population and future burden of pneumococcal pneumonia in the U.S
-
Wroe PC, Finkelstein JA, Ray GT, et al. Aging population and future burden of pneumococcal pneumonia in the U.S. J Infect Dis 2012;205(10):1589-92.
-
(2012)
J Infect Dis
, vol.205
, Issue.10
, pp. 1589-1592
-
-
Wroe, P.C.1
Finkelstein, J.A.2
Ray, G.T.3
-
25
-
-
0033585453
-
Safety of revaccination with pneumococcal polysaccharide vaccine
-
Jackson LA, Benson P, Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999;281(3):243-8.
-
(1999)
JAMA
, vol.281
, Issue.3
, pp. 243-248
-
-
Jackson, L.A.1
Benson, P.2
Sneller, V.P.3
-
26
-
-
0038470983
-
Costeffectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: Role of comorbid conditions and race
-
Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Costeffectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003;138(12):960-8.
-
(2003)
Ann Intern Med
, vol.138
, Issue.12
, pp. 960-968
-
-
Sisk, J.E.1
Whang, W.2
Butler, J.C.3
Sneller, V.P.4
Whitney, C.G.5
-
27
-
-
85060902252
-
Centers for Medicare & Medicaid Services
-
CPT 90471; Data Year
-
Centers for Medicare & Medicaid Services. Physician Fee Schedule Search (CPT 90471; Data Year: 2006). www.cms.gov/apps/physicianfee-schedule/ search/search-criteria.aspx.
-
(2006)
Physician Fee Schedule Search
-
-
-
28
-
-
33645235157
-
-
CDC.
-
CDC. CDC Vaccine Price List. www.cdc.gov/vaccines/programs/vfc/awardees/ vaccine-management/price-list/downloads/2006.pdf.
-
CDC Vaccine Price List
-
-
-
29
-
-
0028235679
-
Cost-effectiveness analysis, extended dominance, and ethics: A quantitative assessment
-
Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making 1994;14(3):259-65.
-
(1994)
Med Decis Making
, vol.14
, Issue.3
, pp. 259-265
-
-
Cantor, S.B.1
-
30
-
-
41149171625
-
What does the value of modern medicine say about the $50000 per qualityadjusted life-year decision rule
-
Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per qualityadjusted life-year decision rule? Med Care 2008;46(4):349-56.
-
(2008)
Med Care
, vol.46
, Issue.4
, pp. 349-356
-
-
Braithwaite, R.S.1
Meltzer, D.O.2
Leslie, D.3
Roberts, M.S.4
-
31
-
-
0026575912
-
How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations
-
Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146(4):473-81.
-
(1992)
CMAJ
, vol.146
, Issue.4
, pp. 473-481
-
-
Laupacis, A.1
Feeny, D.2
Detsky, A.S.3
Tugwell, P.X.4
-
32
-
-
84871627281
-
-
U.S. Census Bureau
-
U.S. Census Bureau. National Population Estimates for the 2000s. www.census.gov/popest/data/national/asrh/2009/f?les/NC-EST2009-ALLDATA-R-File20. csv.
-
National Population Estimates for the 2000s
-
-
-
33
-
-
53349153976
-
Indirect effect of 7-valent pneumococcal conjugate vaccineonpneumococcal colonizationamongunvaccinated household members
-
Millar EV, Watt JP, Bronsdon MA, et al. Indirect effect of 7-valent pneumococcal conjugate vaccineonpneumococcal colonizationamongunvaccinated household members. Clin Infect Dis 2008;47(8):989-96.
-
(2008)
Clin Infect Dis
, vol.47
, Issue.8
, pp. 989-996
-
-
Millar, E.V.1
Watt, J.P.2
Bronsdon, M.A.3
-
34
-
-
33748323238
-
Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: Updated analysis using World Health Organization standardized interpretation of chest radiographs
-
Hansen J, Black S, Shinef?eld H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 2006;25(9):779-81.
-
(2006)
Pediatr Infect Dis J
, vol.25
, Issue.9
, pp. 779-781
-
-
Hansen, J.1
Black, S.2
Shinefeld, H.3
-
36
-
-
0342614917
-
Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine
-
Zielen S, Buhring I, Strnad N, Reichenbach J, Hofmann D. Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine. Infect Immun 2000;68(3):1435-40.
-
(2000)
Infect Immun
, vol.68
, Issue.3
, pp. 1435-1440
-
-
Zielen, S.1
Buhring, I.2
Strnad, N.3
Reichenbach, J.4
Hofmann, D.5
-
37
-
-
34247218436
-
Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
-
Jackson LA, Neuzil KM, Nahm MH, et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2007;25(20):4029-37.
-
(2007)
Vaccine
, vol.25
, Issue.20
, pp. 4029-4037
-
-
Jackson, L.A.1
Neuzil, K.M.2
Nahm, M.H.3
-
38
-
-
75749150864
-
Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middleaged and older adults
-
Musher DM, Manof SB, Liss C, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middleaged and older adults. J Infect Dis 2010;201(4):516-24.
-
(2010)
J Infect Dis
, vol.201
, Issue.4
, pp. 516-524
-
-
Musher, D.M.1
Manof, S.B.2
Liss, C.3
-
39
-
-
72849118939
-
The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years
-
Goldblatt D, Southern J, Andrews N, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009;49(9): 1318-25.
-
(2009)
Clin Infect Dis
, vol.49
, Issue.9
, pp. 1318-1325
-
-
Goldblatt, D.1
Southern, J.2
Andrews, N.3
-
40
-
-
67349118429
-
Age, revaccination, and tolerance effects on pneumococcal vaccination strategies in the elderly: A cost-effectiveness analysis
-
Smith KJ, Zimmerman RK, Nowalk MP, Roberts MS. Age, revaccination, and tolerance effects on pneumococcal vaccination strategies in the elderly: a cost-effectiveness analysis. Vaccine 2009;27(24): 3159-64.
-
(2009)
Vaccine
, vol.27
, Issue.24
, pp. 3159-3164
-
-
Smith, K.J.1
Zimmerman, R.K.2
Nowalk, M.P.3
Roberts, M.S.4
-
41
-
-
79954645991
-
Healthcare utilization and cost of pneumococcal disease in the U.S
-
Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the U.S. Vaccine 2011;29(18):3398-412.
-
(2011)
Vaccine
, vol.29
, Issue.18
, pp. 3398-3412
-
-
Huang, S.S.1
Johnson, K.M.2
Ray, G.T.3
|